Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...

Although metabolic syndrome is associated with higher PsA disease activity, it is not associated with higher PsA-related ...

Arthritis is a common condition that causes pain and inflammation in the joints. If you're looking to manage symptoms of the ...

Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...

Dr. Ariz Sheikh - By following these strategies, you can better manage morning stiffness and improve your comfort and ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

The following is a summary of “Potentially Avoidable Emergency Department Utilization by Persons With Psoriatic Arthritis and ...

Christian Cottingham-Endter has quite a few chronic conditions that make staying active and eating right a challenge. One of them is psoriatic arthritis. But thanks ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

JERSEY CITY, NJ, USA I March 12, 2025 I Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® ...